NCT07423078
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Disease Attributes, +14 more
- Locations
-
- UPMC Hillman Cancer Pittsburgh, Pennsylvania, United States
Clinical trial condition
Recurrence
Explore clinical trials studying Recurrence. Study availability and eligibility vary by location and protocol.
2,310 public trials
520 recruiting studies
Recurrence trial results
NCT05010005
- Conditions
- Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +22 more
- Locations
-
- University of Miami (Data Collection Only) Miami, Florida, United States
- Dana Farber Cancer Institute Boston, Massachusetts, United States
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
NCT06064877
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Disease Attributes, +14 more
- Locations
-
- Banner MD Anderson Cancer Center Gilbert, Arizona, United States
- The University of Arizona Cancer Center Tucson, Arizona, United States
- University of California Los Angeles Los Angeles, California, United States
- Yale School of Medicine - Smilow Cancer Hospital New Haven, Connecticut, United States
NCT05789030
- Conditions
- Autoimmune Diseases, Disease Attributes, Immune System Diseases, +4 more
- Locations
-
- Peking Union Medical College Hospital Beijing, China
NCT06522737
- Conditions
- Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
- Locations
-
- Universitair Ziekenhuis Gent (UZ Gent) Ghent, Belgium
- UZ Leuven - Gasthuisberg Campus Leuven, Belgium
- Vseobecna fakultni nemocnice Prague, Czechia
- Aarhus University Hospital Aarhus, Denmark
NCT05047094
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Disease Attributes, +16 more
- Locations
-
- Sharett institute, Hadassah University Hospital - Ein-Kerem Jerusalem, Israel
- Sheba Medical Center Ramat Gan, Israel
- Tel-Aviv Medical Center Tel Aviv, Israel
Recruiting
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
NCT05544968
- Conditions
- CD30+ Anaplastic Large Cell Lymphoma, CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma, CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma, +19 more
- Locations
-
- Froedtert & the Medical College of Wisconsin Milwaukee, Wisconsin, United States
Recruiting
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
NCT06660368
- Conditions
- Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
- Locations
-
- Moffitt Cancer Center Tampa, Florida, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
NCT05618925
- Conditions
- Disease Attributes, Non Hodgkin's Lymphoma Refractory/Relapsed, Pathologic Processes, +2 more
- Locations
-
- Hoag Memorial Hospital Newport Beach, California, United States
- Texas Oncology Tyler, Texas, United States
Recruiting
Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
NCT07197580
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +23 more
- Locations
-
- Westmead Hospital Sydney, New South Wales, Australia
- Wollongong Hospital Wollongong, New South Wales, Australia
- Austin Health Heidelberg, Victoria, Australia
- Melbourne Theranostic Innovation Centre (MTIC) Melbourne N., Victoria, Australia